大剂量化疗、自体外周血干细胞移植、生物治疗序贯治疗非霍奇金淋巴瘤43例临床研究

Clinical analysis of non-Hodgkin′s lymphoma treated by high does MTX,autologous peripheral stem cell transplantation and biotherapy for 43 cases

目的评价大剂量化疗+自体外周血干细胞移植+生物治疗对非霍奇金淋巴瘤的疗效。方法对43例中、高度恶性非霍奇金淋巴瘤病人序贯进行3周期大剂量甲氨喋呤(HD-MTX),自体外周血干细胞移植,IL-2生物治疗。结果26例NHL-CR组中CR23例(88.5%),RE3例(11.5%),其中死亡1例(3.8%);NHL-PR组17例,CR11例(64.7%),RE6例(35.3%),其中死亡3例(17.6%)。结论该序贯疗法治疗非霍奇金淋巴瘤安全有效,治疗前达到CR患者疗效更佳。

Objective To evaluate the efficacy of non-Hodgkin＇s lymphoma treated by high dose MTX, autologous peripheral stem cell transplantation and biotherapy for 43 cases. Methods Fourty-three patients were treated by three times HD-MTX,APBSCT and biltherapy of IL-2. Results There were 23 cases（ 88.5%）in CR period; 3 cases（11. 5%） in RE period and 1 patient （3. 8%）died in CR group;in PR group, there were 11 cases（64.7%）in CR period; 6 cases（35.3%）in RE period and 3 patients （17. 6%）died. Conclusion These preliminary results suggest that the therapy can be performed safely. It is efficacious therapeutic measure in the patients with non-Hodgkin＇s lymphoma.